Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma
Authors:
Open Access
- 10 May 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1398902
Abstract
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment landscape of relapsed/refractory multiple myeloma. The current Food and Drug Administration approved CAR T cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel both target B cell maturation antigen (BCMA), which is expressed on the surface of malignant plasma cells. Despite deep initial responses in most patients, relapse after anti-BCMA CAR T cell therapy is common. Investigations of acquired resistance to anti-BCMA CAR T cell therapy are underway. Meanwhile, other viable antigenic targets are being pursued, including G protein-coupled receptor class C group 5 member D (GPRC5D), signaling lymphocytic activation molecule family member 7 (SLAMF7), and CD38, among others. CAR T cells targeting these antigens, alone or in combination with anti-BCMA approaches, appear to be highly promising as they move from preclinical studies to early phase clinical trials. This review summarizes the current data with novel CAR T cell targets beyond BCMA that have the potential to enter the treatment landscape in the near future.Keywords
This publication has 158 references indexed in Scilit:
- Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyTransplantation and Cellular Therapy, 2023
- Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricideCytotherapy, 2023
- The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patientsCancer Cell, 2023
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyThe Lancet, 2021
- Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7Molecular Therapy, 2021
- Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell TherapiesCell Systems, 2020
- Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell KillingCancer Cell, 2017
- Chimeric antigen receptor T cell therapy: 25years in the makingBlood Reviews, 2016
- CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myelomaJournal of Cellular Immunotherapy, 2016
- Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5DBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 2001